Evotec SE (EVO) Net Income towards Common Stockholders (2009 - 2025)

Evotec SE (EVO) reported Net Income towards Common Stockholders of -$120.4 million for Q4 2025, up 42.5% on a YoY basis from -$84.5 million in Q4 2024, and down 240274.03% sequentially from -$50074.1 in Q3 2025.

Evotec SE (EVO) Net Income towards Common Stockholders (2009 - 2025) Analysis & Trends

Evotec SE (EVO) has 9 years of Net Income towards Common Stockholders data on file, last reported at -$120.4 million in Q4 2025.

  • For the quarter ending Q4 2025, Net Income towards Common Stockholders rose 42.5% year-over-year to -$120.4 million; the trailing twelve-month figure through Mar 2026 stood at -$120.4 million (up 42.49% YoY), and the FY2025 full-year result was -$120.5 million, up 42.49% from the prior year.
  • Net Income towards Common Stockholders declined to -$120.4 million in Q4 2025, from -$50074.1 in the prior quarter.
  • In the past five years, Net Income towards Common Stockholders ranged from a high of $246.3 million in Q4 2021 to a low of -$209.3 million in Q4 2024.
  • A 5-year average of -$23.5 million and a median of -$29810.4 in 2022 frame the typical range for Net Income towards Common Stockholders.
  • Across the five-year window, Net Income towards Common Stockholders surged 9714.16% in 2021 and sank 240.15% in 2024, its largest moves.
  • Tracing EVO's Net Income towards Common Stockholders over 5 years: stood at $246.3 million in 2021, then tumbled by 172.84% to -$179.4 million in 2022, then soared by 49.69% to -$90.2 million in 2023, then sank by 131.96% to -$209.3 million in 2024, then surged by 42.5% to -$120.4 million in 2025.
  • Business Quant data shows EVO's Net Income towards Common Stockholders at -$120.4 million in Q4 2025, -$50074.1 in Q3 2025, and -$209.3 million in Q4 2024.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Net Income (Qtr)
1 Haleon 89.06 Bn 87.19 Bn - -
2 Teva Pharmaceutical Industries 35.81 Bn 32.07 Bn 1.97 Bn 370.00 Mn
3 Zoetis 32.50 Bn 30.56 Bn 1.62 Bn 601.00 Mn
4 Takeda Pharmaceutical 27.51 Bn 23.45 Bn 4.39 Bn -2.35 Bn
5 United Therapeutics 23.19 Bn 21.04 Bn 648.10 Mn 274.90 Mn
6 RedHill Biopharma 21.76 Bn 21.76 Bn - -
7 Viatris 20.28 Bn 18.47 Bn 1.16 Bn 176.40 Mn
8 Neurocrine Biosciences 17.72 Bn 16.40 Bn 800.70 Mn 197.90 Mn
9 Elanco Animal Health 12.56 Bn 12.13 Bn 785.00 Mn 57.00 Mn
10 Evotec SE 345.39 Mn 344.87 Mn - -

Historic Data

Download Data
DateValue
Dec 31, 2025 -120.37 Mn
Sep 30, 2025 -50,074.14
Dec 31, 2024 -209.31 Mn
Sep 30, 2024 -59,430.15
Dec 31, 2023 -90.24 Mn
Sep 30, 2023 42,406.04
Jun 30, 2023 -13,888.14
Dec 31, 2022 -179.36 Mn
Sep 30, 2022 47,666.17
Jun 30, 2022 -29,810.36
Mar 31, 2022 -82,202.26
Dec 31, 2021 246.25 Mn
Sep 30, 2021 158,344.09
Jun 30, 2021 72,274.35
Mar 31, 2021 63,571.06
Dec 31, 2020 7.48 Mn
Sep 30, 2020 -1,646.99
Dec 31, 2019 42.23 Mn
Sep 30, 2010 170,478.98
Jun 30, 2010 151,033.82